The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder.

INTERVENTION: Trade Name: cycloserine Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use CONDITION: Obsessive��Compulsive Disorder ; MedDRA version: 9.1 Level: LLT Classification code 10029898 Term: Obsessive‐compulsive disorder PRIMARY OUTCOME: Main Objective: The aim of this pilot‐study is to establish the potential efficacy of D‐cycloserine (DCS), a partial NMDA agonist, in accelerating and/or augmenting the effect of exposure and response prevention (ERP) in the treatment of obsessive‐compulsive disorder (OCD). Primary end point(s): Acceleration of the treatment effect of ERP is taken as the primary outcome measure. ; The differences in scores on the Y‐BOCS (clinical interview) between baseline and at several time points will be taken as the main measurement Secondary Objective: Are the effects of D‐cycloserine, if established, maintained in a follow‐up period of 3 months? INCLUSION CRITERIA: ‐ Patients with a primary DSM‐IV diagnosis of OCD with an age of 18 years and older as established with the Structural Clinical Interview for axis I DSM‐IV Disorders (SCID I) ‐ Obsessive‐compulsive complaints has to be such that exposure in vivo is feasible at the outpatient department, in the clinic or the direct environment. ‐ Patients have to understand the rationale of exposure therapy and there has to be a readiness to participate in exposure sessions. ‐ If a patient uses medication, dosages have to be stable (no changes in the last 2 months and during the study period). ‐ Negative pregnancy test (ß‐HCG in urine). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range